Article
Hematology
Kelley R. Jordan, Cory R. Wyatt, Meghan E. Fallon, Randy Woltjer, Edward A. Neuwelt, Quifang Cheng, David Gailani, Christina Lorentz, Erik Tucker, Owen J. T. McCarty, Monica T. Hinds, Khanh P. Nguyen
Summary: Pharmacological targeting of FXI with the anti-FXI antibody 14E11 enhances the early stages of experimental venous thrombus resolution in wild-type CD1 mice. This treatment reduces thrombus weight and volume, decreases circulating monocytes, and reduces macrophage content within thrombi. Collagen deposition is increased in the early stages while CD31 and smooth muscle cell actin expression is increased in the later stages of thrombus resolution.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Review
Biochemistry & Molecular Biology
Reiner K. Mailer, Chandini Rangaswamy, Sandra Konrath, Jonas Emsley, Thomas Renne
Summary: The plasma protein factor XII, as the liver-derived zymogen of serine protease FXIIa, plays a key role in thrombosis and inflammation. Growing evidence suggests that FXIIa-mediated thrombo-inflammation is crucial in various pathological states, and increased FXIIa levels are associated with hypercholestemlemia and hypertriglyceridemia.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2022)
Article
Hematology
Aleksandr Shamanaev, Maxim Litvak, Ivan Ivanov, Priyanka Srivastava, Mao-Fu Sun, S. Kent Dickeson, Sunil Kumar, Tracey Z. Z. He, David Gailani
Summary: FXII plays a crucial role in the pathogenesis of diseases such as hereditary angioedema and surface-triggered thrombosis. Its activation and activity are enhanced when it binds to a surface. Recent studies on the structure and enzymology of FXII provide insights into its relationship with pathology and potential therapeutic targets for thrombo-inflammatory disorders.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2023)
Review
Cardiac & Cardiovascular Systems
Raffaele De Caterina, Domenico Prisco, John W. Eikelboom
Summary: This paper reviews the potential of drugs targeting factor XI in anticoagulant therapy, along with ongoing clinical trials and future research directions.
EUROPEAN HEART JOURNAL
(2023)
Review
Hematology
Karsten Engseth Kluge, Ingebjorg Seljeflot, Harald Arnesen, Torstein Jensen, Sigrun Halvorsen, Ragnhild Helseth
Summary: In this review, observational and experimental studies on factors XI and XII as potential targets for anticoagulant therapy are discussed. Low concentrations of FXI are found to be protective against ischemic stroke and venous thrombosis, indicating its potential as a target for antithrombotic therapy. The potential of targeting FXII for preventing thrombosis is still unclear, with conflicting results from different studies.
THROMBOSIS RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Antonio Greco, Claudio Laudani, Marco Spagnolo, Federica Agnello, Denise Cristiana Faro, Simone Finocchiaro, Marco Legnazzi, Maria Sara Mauro, Placido Maria Mazzone, Giovanni Occhipinti, Carla Rochira, Lorenzo Scalia, Davide Capodanno
Summary: Therapeutic anticoagulation is used to prevent or treat blood clots, but it can increase the risk of bleeding. Inhibitors of Factor XI (FXI) show promise in reducing the adverse events of anticoagulation. Large-scale phase 3 clinical trials are needed to confirm the role of FXI inhibitors and determine their clinical indications.
Article
Hematology
Rowan Frunt, Hinde El Otmani, Bubacarr Gibril Kaira, Steven de Maat, Coen Maas
Summary: Medical device associated thrombosis is a significant clinical issue caused by Factor XII binding to non-natural surface materials and activating the contact pathway. The absence of a publicly available crystal structure of full-length FXII has led to the exploration of the AlphaFold Protein Structure Database's model structure. By combining this model with previous studies, opportunities for selectively blocking FXII's contribution in medical device associated thrombosis can be identified.
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Magdolna Nagy, Alejandro Pallares Robles, Mayken Visser, Thomas Koeck, Vincent ten Cate, Arina J. ten Cate-Hoek, Stephan Schwers, Stefan Heitmeier, Hugo ten Cate, Philipp S. Wild, Henri M. H. Spronk
Summary: This study found that FXIa levels were elevated in patients with acute VTE and were associated with recurrent VTE, suggesting a significant risk contribution of FXI activation to VTE. The findings support the use of FXIa inhibition in the setting of acute VTE.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Anh T. P. Ngo, Kelley R. Jordan, Paul A. Mueller, Matthew W. Hagen, Stephanie E. Reitsma, Cristina Puy, Alexey S. Revenko, Christina U. Lorentz, Erik I. Tucker, Quifang Cheng, Monica T. Hinds, Sergio Fazio, Brett P. Monia, David Gailani, Andras Gruber, Hagai Tavori, Owen J. T. McCarty
Summary: The study indicates that pharmacological targeting of FXI can reduce atherogenesis in Ldlr(-/-) mice, preventing or slowing the progression of atherosclerosis.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Review
Cardiac & Cardiovascular Systems
Charles Hsu, Edward Hutt, Daniel M. Bloomfield, David Gailani, Jeffrey I. Weitz
Summary: Hemostasis and thrombosis are closely linked, with factor XI inhibitors potentially providing a safer alternative to current anticoagulants. Clinical studies are ongoing to determine the efficacy of factor XI inhibitors in attenuating thrombosis without disrupting hemostasis.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Review
Hematology
James C. Fredenburgh, Jeffrey I. Weitz
Summary: Oral anticoagulants are widely used for preventing and treating thrombosis. Direct oral anticoagulants (DOACs) such as dabigatran and apixaban have replaced traditional anticoagulants. New DOACs like asundexian and milvexian, targeting FXIa, offer potential advantages over existing ones.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Cardiac & Cardiovascular Systems
Maria Eugenia de la Morena-barrio, Javier Corral, Cecilia Lopez-Garcia, Victor Alonso Jimenez-Diaz, Antonia Minano, Pablo Juan-Salvadores, Maria Asuncion Esteve-Pastor, Jose Antonio Baz-Alonso, Ana Maria Rubio, Francisco Sarabia-Tirado, Miguel Garcia-Navarro, Juan Garcia-Lara, Francisco Marin, Vicente Vicente, Eduardo Pinar, Sergio Jose Canovas, Gonzalo de la Morena
Summary: In this study, the factors involved in the contact pathway during aortic valve replacement were analyzed, and their impact on the development of thromboembolic complications was assessed. The results showed that TAVR or SAVR did not significantly activate the contact pathway. However, there was a significant reduction in FXI levels during the SAVR procedure, which was associated with a lower incidence of thrombotic events.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Hematology
Ming Li, Shibo Duan, Guowei Xu, Song Li, Min Sun, Xiuzhen Hou, Yan Jin
Summary: This study found that cerebral venous sinus thrombosis (CVST) has become a rare but potentially life-threatening condition in perinatal women. The levels of plasma coagulation factors X, XI, and XII were found to be associated with the diagnosis of CVST in perinatal women.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
(2023)
Article
Multidisciplinary Sciences
Yang Cao, Yuchen Wang, Zhenqi Zhou, Calvin Pan, Ling Jiang, Zhiqiang Zhou, Yonghong Meng, Sarada Charugundla, Tao Li, Hooman Allayee, Marcus M. Seldin, Aldons J. Lusis
Summary: Tissue-tissue communication through endocrine factors is crucial for physiological homeostasis. A study on mice showed that coagulation factor XI (FXI), a protein derived from the liver, protects against diastolic dysfunction, a key trait of heart failure with preserved ejection fraction. FXI was found to activate the BMP-SMAD1/5 pathway in the heart and inhibit genes associated with inflammation and fibrosis, by cleaving and activating extracellular matrix-associated BMP7. This study reveals a protective role of FXI in heart injury that is separate from its role in blood coagulation.
Article
Hematology
Ophira Salomon, David Gailani
Summary: Therapeutic inhibitors targeting FXI(a) are being evaluated as potential treatments for preventing thrombosis, with the expectation of having a smaller impact on hemostasis than current anticoagulants targeting thrombin or factor Xa. However, some patients on these inhibitors may still experience abnormal bleeding or require emergent surgery, necessitating the development of strategies to address these situations. Treatment with antifibrinolytic agents and low doses of recombinant factor VIIa has been effective in preventing abnormal bleeding in FXI-deficient patients, suggesting a potential strategy for patients on therapeutic FXI(a) inhibitors experiencing bleeding or requiring invasive procedures.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Oncology
Toma S. Omofoye, Anganile Kalinga, Ramapriya Ganti, Frank J. Minja, Timothy B. Rooney
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Prarthna V. Bhardwaj, Renuka Dulala, Senthil Rajappa, Chandravathi Loke
Summary: The management of breast cancers in India needs greater emphasis on awareness, early detection, standard pathologic testing, and cost-effective solutions. With standardized management, outcomes similar to those of developed countries can be expected. Additionally, clinical trials aimed at a more diverse population in LMICs like India should be undertaken.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria E. Forbes, Mary D. Chamberlin, Vincent Dusabejambo, Tim Walker, Steve P. Bensen, Norrisa Haynes, Kathryn Nunes, Veauthyelau Saint-Joy, Frederick L. Makrauer
Summary: Global health education needs to adapt to the challenges we face, such as inequities and pandemics. Virtual teaching models are effective in delivering global health education and improving outcomes through bidirectional learning and equitable partnerships.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Tefta Isufaj Haliti, Ilir Hoxha, Rubena Mojsiu, Rohini Mandal, Goksu Goc, Kreshnike Dedushi Hoti
Summary: The IOTA Simple Rules have high diagnostic performance in distinguishing between benign and malignant adnexal masses, providing a reliable tool for early diagnosis of ovarian cancer.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Cecilia Felix Penido Mendes de Sousa, Jared Pasetsky, Gustavo Nader Marta, Megan Kassick, Fabio Ynoe Moraes, Luqman K. Dad
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary D. Chamberlin, Dafina Ademi Islami, Shqiptar Demaci, Richard J. Barth Jr
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha
Summary: The evidence suggests that lifestyle factors such as alcohol and coffee intake may increase the risk of lung cancer, while tea intake may have a protective effect. However, the quality of evidence is currently low and further research is needed.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary Chamberlin, Christopher Booth, Gabriel A. Brooks, Achille Manirakiza, Fidel Rubagumya, Verna Vanderpuye
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anne Christine Buteau, Alicia Castelo-Loureiro, Regina Barragan-Carrillo, Suyapa Bejarano, Alba J. Kihn-Alarcon, Enrique Soto-Perez-de-Celis
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Ilir Hoxha, Fitim Sadiku, Lot Hoxha, Midhet Nasim, Marie Anne Christine Buteau, Krenare Grezda, Mary D. Chamberlin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)